GlycoNex Inc.

GlycoNex Inc. is a leading pharmaceutical company dedicated to the development of innovative antibody drugs targeting tumor-associated carbohydrate antigens (TACAs). Founded in 2001 in collaboration with The Biomembrane Institute (TBI) from Washington University, GlycoNex Inc. has established itself as a pioneer in combining cancer-related glycan identification with human monoclonal antibody development.

GlycoNex Inc. possesses a comprehensive technological platform for anti-glycan antibody development, supported by multiple licensed patents. The company’s pipeline includes both novel drug development and biosimilars, with new drugs selected and developed through rigorous antigen/antibody characterization and cell line development. GlycoNex Inc. is committed to advancing healthcare through its innovative research and development efforts.

The primary address of GlycoNex Inc. is 8F., No. 97, Section 1, Xintai 5th Rd., Xizhi District, New Taipei City, TW. GlycoNex Inc. continually seeks opportunities for out-licensing products and collaborative co-development to further its mission of bringing cutting-edge treatments to patients worldwide. We invite the manager of GlycoNex Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial reach.